ZURICH—Roche Holding AG said Monday it was buying Danish biopharmaceutical firm Santaris Pharma for as much $450 million, as the Swiss giant looks for ways to develop drugs for diseases difficult to address with existing medicines.. Roche, based in Basel, Switzerland, said in a statement that it would make an initial cash payment of $250 million for privately held Santaris, which specializes in relatively new RNA-targeting therapeutics. Roche will make additional payments of as much as $200 million if the company reaches certain...
  